Goswami Spondita, Hartz Sarah M, Oliver Amy, Jackson Sacha, Ogungbenle Tomi, Evans Alissa, Linnenbringer Erin, Moulder Krista L, Morris John C, Mozersky Jessica
Bioethics Research Center, Washington University in St Louis, St Louis, Missouri.
Knight Alzheimer Disease Research Center, Washington University in St Louis, St Louis, Missouri.
JAMA Netw Open. 2025 May 1;8(5):e252919. doi: 10.1001/jamanetworkopen.2025.2919.
While available evidence suggests there are not major psychosocial harms of return of research results, there are limited data on uptake of Alzheimer disease (AD) research results or reasons for declining to learn results among participants in AD research studies.
To quantitatively and qualitatively evaluate who declines to learn individual AD biomarker research results and what factors are associated with the decision.
DESIGN, SETTING, AND PARTICIPANTS: This observational cohort study was conducted between November 1, 2020, and April 15, 2024, among participants aged 65 years or older with unimpaired cognition and available biomarker data (apolipoprotein E genotype and either imaging [amyloid positron emission tomography and magnetic resonance imaging] or plasma amyloid level) enrolled in a longitudinal cohort of cognitive aging at the Knight Alzheimer Disease Research Center.
Participants with no prior option to receive research results were offered the option to learn these results.
The primary outcome was the decision to receive AD research biomarker results. Associations of this decision with demographic factors including self-identified race, parental history of AD, age, gender, and type of biomarker result offered (imaging or plasma) were assessed using χ2 tests and semiparametric log-binomial regression. Semistructured qualitative interviews with a subset of participants who declined receiving research results explored reasons for declining.
Of the 274 participants who were offered their research results (mean [SD] age, 75.9 [5.8] years; 158 women [58%]; 35 Black [13%]; and 239 White [87%]), 110 (40%) declined. Black participants were more likely to decline than White participants (adjusted risk ratio, 1.89; 95% CI, 1.43-2.50). Participants with a known parental history of AD dementia were more likely to decline than those without (adjusted risk ratio, 1.49; 95% CI, 1.12-1.98). Qualitative interviews found the following reasons for declining: knowing would be a burden, negative experiences and perceptions of AD dementia, feeling good about memory currently, familial burden, already being prepared, and the uncertainty of results.
In this study of participants enrolled in a longitudinal aging study offered their research results, those with a parental history of AD dementia and Black participants were significantly more likely to decline. Qualitative interviews suggest that a family history of AD may create negative experiences and perceptions of the disease, which may influence the decision to learn results. Further research is needed to better understand racial differences in uptake and ensure that the choice to receive research results reflects individual preferences and wishes.
虽然现有证据表明研究结果的反馈不存在重大的社会心理危害,但关于阿尔茨海默病(AD)研究结果的接受情况或AD研究参与者拒绝了解结果的原因的数据有限。
定量和定性评估谁会拒绝了解个体AD生物标志物研究结果以及哪些因素与该决定相关。
设计、地点和参与者:这项观察性队列研究于2020年11月1日至2024年4月15日在骑士阿尔茨海默病研究中心的认知衰老纵向队列中,对65岁及以上认知未受损且有可用生物标志物数据(载脂蛋白E基因型以及成像[淀粉样蛋白正电子发射断层扫描和磁共振成像]或血浆淀粉样蛋白水平)的参与者进行。
之前没有选择接收研究结果的参与者被提供了解这些结果的选项。
主要结局是决定是否接收AD研究生物标志物结果。使用卡方检验和半参数对数二项回归评估该决定与人口统计学因素(包括自我认定的种族、AD家族史、年龄、性别以及提供的生物标志物结果类型[成像或血浆])之间的关联。对一部分拒绝接收研究结果的参与者进行半结构化定性访谈,以探究拒绝的原因。
在274名被提供研究结果的参与者中(平均[标准差]年龄为75.9[5.8]岁;158名女性[58%];35名黑人[13%];239名白人[87%]),110名(40%)拒绝了。黑人参与者比白人参与者更有可能拒绝(调整后的风险比为1.89;95%置信区间为1.43 - 2.50)。有已知AD痴呆家族史的参与者比没有家族史的参与者更有可能拒绝(调整后的风险比为1.49;95%置信区间为1.12 - 1.98)。定性访谈发现拒绝的原因如下:知道结果会是一种负担、对AD痴呆有负面经历和认知、目前对自己的记忆力感觉良好、家庭负担、已经做好心理准备以及结果的不确定性。
在这项对参与纵向衰老研究并被提供研究结果的参与者的研究中,有AD痴呆家族史的参与者和黑人参与者显著更有可能拒绝。定性访谈表明,AD家族史可能会产生对该疾病的负面经历和认知,这可能会影响了解结果的决定。需要进一步研究以更好地理解接受情况的种族差异,并确保接收研究结果的选择反映个人偏好和意愿。